Journal of IiMER genomics. Abstract: Establishing new mechanistic and diagnostic paradigms for ME/CFS Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is the last major disease we know almost nothing about. To date, very little is understood about the cause of ME/CFS: years of searching for a common triggering pathogen have been fruitless, and no biological assays exist to facilitate diagnosis. Recent evidence strongly supports ME/CFS as a molecular disease, even if many of the symptoms are cognitive and muscular, which indicates that molecular studies will help to understand and diagnose this disease, and that molecular therapies have the potential to treat it. The time is ripe for this change in perspective, because researchers now have highly advanced, sensitive, and comprehensive molecular technologies at their disposal, and the beginnings of a molecular understanding with which to unravel this disease. We are working to unravel the molecular path from health to ME/CFS, and develop cost-effective technology for diagnosis and drug discovery – offering a new level of precision for researchers and physicians to tackle this complex illness. All of this research is being carried out in close collaboration with physician, patient, and advocate communities, including direct involvement of patient partners and dedicated outreach efforts to broaden awareness of the disease. We aim to implement an interdisciplinary, integrative, inclusive precision approach to ME/CFS to fundamentally change how this disease is understood and managed, and most importantly, to give new hope to patients. Invest in ME Research www.investinme.org Page 79 of 82
80 Publizr Home